[go: up one dir, main page]

ES2068587T3 - Medicamentos tumorales sustituidos con polieter. - Google Patents

Medicamentos tumorales sustituidos con polieter.

Info

Publication number
ES2068587T3
ES2068587T3 ES91910296T ES91910296T ES2068587T3 ES 2068587 T3 ES2068587 T3 ES 2068587T3 ES 91910296 T ES91910296 T ES 91910296T ES 91910296 T ES91910296 T ES 91910296T ES 2068587 T3 ES2068587 T3 ES 2068587T3
Authority
ES
Spain
Prior art keywords
substituted
polyeter
replaced
amino group
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91910296T
Other languages
English (en)
Inventor
Hans-J Sinn
Hans-Hermann Schrenk
Wolfgang Maier-Borst
Eckhard Friedrich
Georgi Graschew
Dieter Woehrle
Thomas Klenner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4017439A external-priority patent/DE4017439C2/de
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Application granted granted Critical
Publication of ES2068587T3 publication Critical patent/ES2068587T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
  • Polyethers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SUSTANCIAS PARA TRATAR O DIAGNOSTICAR TUMORES, CON UNA CONCENTRACION PREFERENTE EN EL TUMOR, QUE SE CARACTERIZAN PORQUE TIENEN AL MENOS DOS GRUPOS HIDROXILO Y/O AMINO FENOLICOS, AL MENOS UN GRUPO AMINO OLIFATICO O AL MENOS UN GRUPO HIDROXILO/AMINO FENOLICO Y AL MENOS UN GRUPO AMINO ALIFATICO Y ESTOS GRUPOS SON SUSTITUIDOS POR CADENAS DE POLIETILENGLICOL CUYO PRADO DE POLIMERIZACION N ES DE 5 A 250 Y CUYO GRUPOS HIDROXILO TERMINAL ES SUSTITUIDO POR ALQUILESTER C SUB 1-C SUB 12 O ETER, SIENDO CADA SUSTANCIA SUSTITUIDA POR AL MENOS DOS CADENAS POLIETILENGLICOL.
ES91910296T 1990-05-30 1991-05-29 Medicamentos tumorales sustituidos con polieter. Expired - Lifetime ES2068587T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4017439A DE4017439C2 (de) 1990-05-30 1990-05-30 Polyethersubstituierte Tumormittel

Publications (1)

Publication Number Publication Date
ES2068587T3 true ES2068587T3 (es) 1995-04-16

Family

ID=6407498

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91910296T Expired - Lifetime ES2068587T3 (es) 1990-05-30 1991-05-29 Medicamentos tumorales sustituidos con polieter.

Country Status (7)

Country Link
EP (1) EP0485563B1 (es)
JP (1) JP2640293B2 (es)
AT (1) ATE115864T1 (es)
DE (2) DE59103985D1 (es)
DK (1) DK0485563T3 (es)
ES (1) ES2068587T3 (es)
WO (1) WO1991018630A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08501097A (ja) * 1992-09-04 1996-02-06 ザ ゼネラル ホスピタル コーポレーション 臨床診断及び治療用部分を含む生体適合性ポリマー
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
EP0664713B1 (en) * 1992-10-14 2000-01-19 Nycomed Imaging As Therapeutic and diagnostic imaging compositions and methods
KR950703582A (ko) * 1992-10-14 1995-09-20 조이스 이. 마임스 킬레이트화 중합체(chelating polymers)
US5817292A (en) * 1992-10-14 1998-10-06 Nycomed Imaging As MR imaging compositions and methods
US5605672A (en) * 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
GB9408746D0 (en) * 1994-05-03 1994-06-22 Scotia Holdings Plc Tumour locallising photosensitising compounds
US7255851B2 (en) 1994-07-01 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
TW319763B (es) 1995-02-01 1997-11-11 Epix Medical Inc
DE19514087A1 (de) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein
DE19706490C1 (de) * 1997-02-19 1998-09-17 Deutsches Krebsforsch Verfahren zur Herstellung von Säureamiden und zur Metallierung von Verbindungen und Verwendung der nach den Verfahren hergestellten Verbindungen
ES2213899T3 (es) * 1997-04-29 2004-09-01 Amersham Health As Agentes de contraste utilizados en tecnicas de formacion de imagen en base a la luz.
ATE283271T1 (de) 1998-08-28 2004-12-15 Destiny Pharma Ltd Porphyrin derivate, ihre verwendung in der photodynamischen therapie und diese enthaltende medizinische geräte
GB0005855D0 (en) 2000-03-10 2000-05-03 Scotia Holdings Plc Compounds for pdt
ITPD20030174A1 (it) * 2003-07-31 2003-10-29 Univ Padova Coniugati polimerici per diagnostica e terapia
IL168184A (en) * 2005-04-21 2011-11-30 Univ Ariel Res & Dev Co Ltd Use of a ligand-photosensitizer conjugate in combination with a chemiluminescent agent in the manufacture of a medicament for photodynamic therapy
US8853247B2 (en) 2007-11-02 2014-10-07 Nektar Therapeutics Oligomer-nitroimidazole anti-infective conjugates

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4824659A (en) * 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
DE3546150A1 (de) * 1985-06-24 1987-01-22 Hoechst Ag Membrananker-wirkstoffkonjugat, seine herstellung sowie seine verwendung
US4830847A (en) * 1985-06-28 1989-05-16 The Procter & Gamble Company Diphosphonate-derivatized macromolecules
IN165717B (es) * 1986-08-07 1989-12-23 Battelle Memorial Institute
AU611932B2 (en) * 1987-08-21 1991-06-27 Wellcome Foundation Limited, The Novel complex
JPH0751592B2 (ja) * 1987-12-28 1995-06-05 帝人株式会社 シクロトリフォスファゼン誘導体
DE3809671A1 (de) * 1988-03-18 1989-09-28 Schering Ag Porphyrin-komplexverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
JPH0796558B2 (ja) 1988-03-31 1995-10-18 協和醗酵工業株式会社 修飾ポリペプチド
AU5858690A (en) 1989-06-14 1991-01-08 Cetus Corporation Polymer/antibiotic conjugate
DE4017439C2 (de) * 1990-05-30 1994-06-23 Deutsches Krebsforsch Polyethersubstituierte Tumormittel

Also Published As

Publication number Publication date
JP2640293B2 (ja) 1997-08-13
EP0485563B1 (de) 1994-12-21
DK0485563T3 (da) 1995-03-20
DE59103985D1 (en) 1995-02-02
JPH05501885A (ja) 1993-04-08
WO1991018630A1 (de) 1991-12-12
DE4139715A1 (de) 1993-06-03
EP0485563A1 (de) 1992-05-20
DE4139715C2 (de) 1994-08-11
ATE115864T1 (de) 1995-01-15

Similar Documents

Publication Publication Date Title
ES2068587T3 (es) Medicamentos tumorales sustituidos con polieter.
ES507033A0 (es) Metodo y aparato para extruir polimeros de etileno lineales de estrecha distribucion de peso molecular.
IT8026950A0 (it) Particelle di sostanze solubili in lipoidi e composizioni biologicamente attive che le contengono.
BR8101341A (pt) Composicao polimera compatibilizada e copolimero por blocos
ES2174895T3 (es) Combinaciones metalicas complejas con contenido en carbenos heterociclicos.
SE7612432L (sv) Komposition och forfarande for dispergering av hogmolekylera flockningspolymerer i vatten
DE3686939D1 (de) Mittels strahlung sterilisierbare propylenpolymerzusammensetzungen und daraus hergestellte gegenstaende.
BE900650A (fr) Composition d'endotoxine detoxifiee raffinee et d'un extrait d'un microorganisme soluble dans la pyridine.
EP0215662A3 (en) Anti-tumor protease preparations
FI830075A7 (fi) Polymeerikoostumuksia ja niiden käyttö liima-aineina tai liima- aineissa ja muissa koostumuksissa.
DE69332688D1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
DE69000104D1 (de) Hoch wasserabsorbierende pulverige polymerzusammensetzung.
DE3382356D1 (de) Fluorsubstituierte mischpolymerisate sowie damit behandelte textilfasern.
SE399135B (sv) Ljusherdbar kopieringsmassa
ES2088633T3 (es) Estabilizantes polisiloxanicos que contienen grupos fenol y grupos oxamidicos estericamente impedidos.
BR8108557A (pt) Produtos de adicao oxalquilados de polimeros por blocos de oxido de etileno-oxido de propileno e eteres bis-glicidilicos e sua aplicacao
SE8103677L (sv) Modifierade glukosaminoglykaner med antilipemisk verkan och i huvudsak saknande antikoagulantverkan
EP0146106A3 (de) Thermoplastische Polyamide als Duftstoffträger
SE8000466L (sv) Polymeriska immunreglerade medel
DE69216113D1 (de) Öl- und brennölzusammensetzungen
ES2069543T3 (es) Procedimiento para la obtencion de poliglicoleteres cerrados en los grupos terminales.
ATE22899T1 (de) Antithrombin-heparin komplex.
ATE146191T1 (de) Galactomannanderivate zur umhüllung oder einbettung von arzneimittelwirkstoffen
SE8601563D0 (sv) Matrismaterial, forfarande for framstellning derav och anvendning derav
FI853095L (fi) Foerfarande foer aotervinning av en gelbildande polysackarid, aotervunnen polysackarid och gel bildad daermed.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 485563

Country of ref document: ES